Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Announces Last Patient Dosing of Phase 1b/2a of Batoclimab in NMOSD

Date|2021-07-19

Related Data

HanAll Biopharma (KRX: 009420.KS) today announced that its partner of HL161 (batoclimab) & HL036 (tanfanercept)​ for the Chinese market, Harbour BioMed, reported last patient dosing in a Phase 1b/2b of batoclimab in acute neuromyelitis optica spectrum disorder​ (NMOSD). This is the first PoC study for the treatment of NMOSD in the anti-FcRn space. 

 

For the further information, please refer to the link below. 

- HBM press release link: https://www.harbourbiomed.com/news/158.html​

NextHanAll Biopharma Submits IND for Second Phase 3 (VELOS-3) of HL036 in Dry Eye Disease

PrevHanAll's Partner HBM Announces Positive Topline Results from Phase 2 of Batoclimab in MG

List